Patients with histological diagnosis of oesogastric or pancreatic adenocarcinoma
Resectable tumors
Patients able to have a laparoscopy
In case of absence of peritoneal invasion on the laparoscopy, patient candidate to a chemotherapy schedule by FLOT or FOLFOX in perioperative setting for oesogastric adenocarcinoma, or FOLFIRINOX in perioperative setting for pancreatic adenocarcinoma
Registration in a national health care system (CMU included)
Patient speak and understand the french
You may not be if
Histology other than adenocarcinoma
Metastatic disease
History of previous treatment with oxaliplatine
History of systemic chemotherapy administration within 5 years prior to inclusion,
Patient with an non balanced progressive condition/disease (liver failure, renal failure (creatinine clearance \<30mL/min), respiratory failure, congestive heart failure, myocardial infarction in the last 6 months, etc.),
Patient on curative dose anticoagulant,
Patient with complete dihydropyrimidine dehydrogenase deficiency (Uracilemia ≥ 150 ng/ml),
Patient not operable for the pathology concerned,
Pregnant or breastfeeding woman, woman of childbearing age who has not performed a pregnancy test before the procedure,
Patient with legal incapacity (person deprived of liberty or under curatorship, stutorship, safeguard of justice),
Patient who, for psychiatric, social, family or geographical reasons, cannot be followed and/or comply with the requirements of the study,,
Discovery of peritoneal invasion during the peritoneal exploratory of the laparoscopy
Clareo Health | Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1
